News
VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...
Researchers have discovered in a new study that glucocorticoid-induced adrenal insufficiency (GIAI) was rare (1.9%) in ...
VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results from ...
Glucocorticoid-induced adrenal insufficiency was lower in prevalence than previously estimated among patients with PMR or GCA.
The following is a summary of “Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone,” published in the March 2025 issue of JAMA Network Open by Hansen et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results